Journal article
Continuous reactive crystallization of beta-lactam antibiotics catalyzed by penicillin G acylase. Part II: Case study on ampicillin and product purity
Computers & chemical engineering, v 126, pp 332-341
12 Jul 2019
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Continuous reactive crystallization of beta-lactam antibiotics can ease shortage and contamination concerns for an important class of medicines. With a model of continuous reactive crystallization catalyzed by penicillin G acylase (PGA), a process is developed to ensure purity of the antibiotic product. Guaranteeing the solid-phase purity of ampicillin and cephalexin is important because PGA produces a slightly soluble byproduct, phenylglycine, which can contaminate the antibiotic crystals. In a single well-mixed reactive crystallizer, productivity is optimized and nearly two-fold greater than the non-crystallizing maximum productivity. Process robustness is essential because multiple steady states, only one of which produces pure ampicillin crystals, exist in the well-mixed reactive crystallizer. By combining well-mixed and plug-flow reactive crystallizers in series, crystallization of phenylglycine can be suppressed while high yield and comparable productivity are still achieved. The reactive crystallizer series demonstrates high purity with uncertainty in model parameter values and variability in operating conditions. (C) 2019 Elsevier Ltd. All rights reserved.
Metrics
Details
- Title
- Continuous reactive crystallization of beta-lactam antibiotics catalyzed by penicillin G acylase. Part II: Case study on ampicillin and product purity
- Creators
- Matthew A. McDonald - Georgia Institute of TechnologyAndreas S. Bommarius - Georgia Institute of TechnologyMartha A. Grover - Georgia Institute of TechnologyRonald W. Rousseau - Georgia Institute of Technology
- Publication Details
- Computers & chemical engineering, v 126, pp 332-341
- Publisher
- Elsevier
- Number of pages
- 10
- Grant note
- Cecil J. "Pete" Silas Endowment 1540017 / NSF Center for Pharmaceutical Development (CPD) U01FD006484 / Georgia Research Alliance FDA Center for Drug Evaluation and Research Georgia Institute of Technology's Specialty Separation Center
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Chemical and Biological Engineering
- Web of Science ID
- WOS:000469222800025
- Scopus ID
- 2-s2.0-85064695230
- Other Identifier
- 991021958008604721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Computer Science, Interdisciplinary Applications
- Engineering, Chemical